William Blair reissued their market perform rating on shares of Kezar Life Sciences (NASDAQ:KZR - Free Report) in a report issued on Wednesday,RTT News reports.
Separately, HC Wainwright reiterated a "neutral" rating on shares of Kezar Life Sciences in a research report on Monday, October 14th.
Check Out Our Latest Report on Kezar Life Sciences
Kezar Life Sciences Price Performance
NASDAQ KZR traded up $0.05 during mid-day trading on Wednesday, hitting $7.54. The company's stock had a trading volume of 35,765 shares, compared to its average volume of 74,179. The company has a current ratio of 9.58, a quick ratio of 9.58 and a debt-to-equity ratio of 0.05. Kezar Life Sciences has a 52-week low of $5.20 and a 52-week high of $11.35. The stock's fifty day simple moving average is $7.09 and its two-hundred day simple moving average is $6.84.
Kezar Life Sciences (NASDAQ:KZR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($2.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.20) by $0.40. Equities research analysts anticipate that Kezar Life Sciences will post -11.95 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Kezar Life Sciences
A number of institutional investors and hedge funds have recently bought and sold shares of KZR. Mackenzie Financial Corp acquired a new position in shares of Kezar Life Sciences during the second quarter valued at $35,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Kezar Life Sciences during the second quarter valued at $63,000. BNP Paribas Financial Markets lifted its stake in Kezar Life Sciences by 35.4% in the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company's stock valued at $247,000 after buying an additional 71,543 shares during the period. Ikarian Capital LLC increased its holdings in shares of Kezar Life Sciences by 1.8% in the first quarter. Ikarian Capital LLC now owns 868,992 shares of the company's stock worth $783,000 after acquiring an additional 15,601 shares in the last quarter. Finally, Acuitas Investments LLC grew its holdings in shares of Kezar Life Sciences by 42.8% during the second quarter. Acuitas Investments LLC now owns 986,785 shares of the company's stock worth $592,000 after buying an additional 295,956 shares in the last quarter. Institutional investors and hedge funds own 67.90% of the company's stock.
Kezar Life Sciences Company Profile
(
Get Free Report)
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
Read More
Before you consider Kezar Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kezar Life Sciences wasn't on the list.
While Kezar Life Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
